Evicenter
P&T meetings

BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer
SpyGlass Pharma
Regulatory submission
NDA planned for 2028
Launch
Not announced
Last updated
129 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of BIM-IOL System on other drugs

1 evidence topic · 1 source

Bimatoprost metabolism and systemic exposure: Lumigan labeling

“Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.” (opens the source at this quote in a new tab)

Clinical drug interaction studies

No evidence found.